文献速递其他结缔组织病

肌炎特异性自身抗体亚型与幼年皮肌炎患者对Janus激酶抑制剂治疗反应相关

Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

单中心回顾性研究纳入39例接受JAKi治疗至少6个月的JDM患者,32/39(82%)在6个月内达到部分或完全临床非活动性疾病(CID);抗TIF1γ抗体是JDM起病时唯一与未达到CID相关的因素(P<0.001);JAKi相关不良事件包括9例感染(含5例带状疱疹)和3例体重增加。

要点

  • 39例JDM患者接受JAKi治疗6个月后,32/39(82%)达到部分或完全CID。
  • 抗TIF1γ抗体是JDM起病时唯一与未达到CID相关的因素(P<0.001)。
  • JAKi相关不良事件为9例感染(含5例带状疱疹)和3例体重增加。

核心结论

  • JAKi使大多数新发和难治性JDM患者达到CID,但难治性TIF1γ阳性JDM患者亚组除外;总体耐受性可接受;这些结果需在更大的前瞻性国际队列研究中验证。

研究设计与样本

  • 单中心回顾性研究,纳入39例接受JAKi治疗至少6个月的JDM患者。

主要发现

  • 32/39(82%)患者在JAKi治疗6个月后达到部分或完全CID。
  • 在应答者中,平均激素剂量从1 mg/kg/天降至0 mg/kg/天(P=0.001),所有其他药物均被停用。
  • 多变量分析中,抗转录中介因子1γ(抗TIF1γ)抗体是JDM起病时唯一与未达到CID相关的因素(P<0.001)。
  • 仅在达到CID的患者中观察到从JDM诊断至6个月随访时中位1型IFN评分和血清IFN-α显著下降。
  • JAKi相关不良事件包括9例患者感染(其中5例带状疱疹感染)和3例患者体重增加。

关键数值与推荐

  • 采用PRINTO标准和皮肤疾病活动度评分评估JAKi开始后6个月内达到CID的患者比例。
  • 检测1型IFN基因签名、血清IFN-α和IFN-β蛋白滴度作为潜在应答生物标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 单中心回顾性研究。
  • 这些结果需在更大的前瞻性国际队列研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of Janus kinase inhibitors (JAKi) in a monocentric series of patients with JDM and to identify factors associated with the achievement of clinically inactive disease (CID). METHODS: Single-centre retrospective study of 39 JDM patients treated with JAKi for at least 6 months. The proportion of patients achieving CID within 6 months after initiation of JAKi was assessed using the PRINTO criteria and the Skin Disease Activity Score. Type 1 IFN gene signature, serum IFN-α and IFN-β protein titres were measured as potential response biomarkers. RESULTS: Thirty-nine patients with JDM were included. Partial or complete CID was achieved in 32/39 (82%) patients after 6 months of treatment. In responders, the mean steroid dose decreased from 1 to 0 mg/kg/day (P = 0.001) and all other medications were withdrawn. In multivariable analysis, the presence of anti-transcriptional intermediary factor 1 gamma (anti-TIF1γ) Abs was the only factor at JDM onset associated with the absence of CID (P < 0.001). A significant decrease in the median Type 1 IFN score and serum IFN-α from the diagnosis of JDM to the 6-month follow-up was observed only in patients with CID. JAKi-related adverse events consisted of infections in nine patients (including five herpes zoster infections) and weight gain in three patients. CONCLUSIONS: JAKi induced CID in the majority of new-onset and refractory JDM patients, except in a subset of patients with refractory TIF1γ-positive JDM. Overall tolerance was acceptable. These results need to be validated in a larger prospective international cohort study.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bader-Meunier B, Moreau TRJ, Aeschlimann F, et al. Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis. Rheumatology (Oxford). 2025. PMID: 40411753. doi:10.1093/rheumatology/keaf214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。